Will "The likely first longevity drug is based on s..." make the top fifty posts in LessWrong's 2023 Annual Review?
1
9
Ṁ45Ṁ70
2025
14%
chance
1D
1W
1M
ALL
As part of LessWrong's Annual Review, the community nominates, writes reviews, and votes on the most valuable posts. Posts are reviewable once they have been up for at least 12 months, and the 2023 Review resolves in February 2025.
This market will resolve to 100% if the post The likely first longevity drug is based on sketchy science. This is bad for science and bad for longevity. is one of the top fifty posts of the 2023 Review, and 0% otherwise. The market was initialized to 14%.
Get Ṁ200 play money
More related questions
Related questions
Will "Which skincare products are evidence-based?" make the top fifty posts in LessWrong's 2024 Annual Review?
16% chance
Will "Toward a Broader Definition of Adverse Selection" make the top fifty posts in LessWrong's 2024 Annual Review?
41% chance
Will "Towards Developmental Interpretability" make the top fifty posts in LessWrong's 2023 Annual Review?
69% chance
Will "Model Organisms of Misalignment: The Case for..." make the top fifty posts in LessWrong's 2023 Annual Review?
64% chance
Will "How useful is mechanistic interpretability?" make the top fifty posts in LessWrong's 2023 Annual Review?
29% chance
Will "Against Almost Every Theory of Impact of Inte..." make the top fifty posts in LessWrong's 2023 Annual Review?
27% chance
Will "A stylized dialogue on John Wentworth's claim..." make the top fifty posts in LessWrong's 2023 Annual Review?
26% chance
Will "AI Timelines" make the top fifty posts in LessWrong's 2023 Annual Review?
83% chance
Will "Social Dark Matter" make the top fifty posts in LessWrong's 2023 Annual Review?
19% chance
Will "Killing Socrates" make the top fifty posts in LessWrong's 2023 Annual Review?
18% chance